A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

被引：0
|
作者：
Grant, Cliona [1 ]
Dunleavy, Kieron [1 ]
Hessler, Julieanne [1 ]
Steinberg, Seth M. [2 ]
Pittaluga, Stefania [3 ]
Jaffe, Elaine S. [3 ]
Wilson, Wyndham H. [4 ]
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Rockville, MD USA
[3] NCI, Pathol Lab, Bethesda, MD 20892 USA
[4] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3709.3709
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3709
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HIV-Associated Diffuse Large B-Cell Lymphoma: Outcome With Uniform DA-EPOCH-R Protocol
    Gogia, Ajay
    Kirar, Sudhir
    Sharma, Atul
    Gupta, Ritu
    Mallick, Soumya
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S421 - S421
  • [2] A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Collins, Graham P.
    Eyre, Toby A.
    Linton, Kim M.
    Radford, John
    Vallance, Grant D.
    Soilleux, Elizabeth
    Hatton, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 886 - 890
  • [3] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [4] Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial
    Fjorden, Karin
    Ekberg, Sara
    Kuric, Nevzeta
    Smedby, Karin E.
    Lagerlof, Ingemar
    Larsen, Thomas S.
    Jorgensen, Judit M.
    de Nully Brown, Peter
    Jerkeman, Mats
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 437 - 440
  • [5] Phase I/II Clinical Trial of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Follicular Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 17 - 18
  • [6] Efficacy of DA-EPOCH-R as first-line therapy for diffuse large B-cell lymphoma: a comprehensive review and metaanalysis
    Putra, M. R.
    Nugrahani, A. D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1361 - S1361
  • [7] DA-EPOCH-R Has Comparable Outcomes in De Novo and Transformed Diffuse Large B Cell Lymphoma
    Desai, Sanjal H.
    Chaturvedi, Mansi
    Hameed, Rumaisa
    Sosa, Valentina Baez
    Shenoy, Aarthi
    BLOOD, 2020, 136
  • [8] Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
    Batlevi, Connie Lee
    De Frank, Stephanie
    Stewart, Caitlin
    Hamlin, Paul A.
    Matasar, Matthew J.
    Gerecitano, John F.
    Moskowitz, Alison J.
    Hamilton, Audrey M.
    Zelenetz, Andrew David
    Drullinsky, Pamela
    Straus, David J.
    Kumar, Anita
    Moskowitz, Craig H.
    Dicostanzo, Joanna
    Callan, Devin
    Tsui, Dana
    Rademaker, Jurgen
    Schoder, Heiko
    Ni, Ai
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [10] DA-EPOCH-R Has Comparable Outcomes in De Novo and Transformed Diffuse Large B Cell Lymphoma
    Desai, Sanjal H.
    Chaturvedi, Mansi
    Hameed, Rumaisa
    Sosa, Valentina Baez
    Shenoy, Aarthi
    BLOOD, 2020, 136
12345